Mira Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Board of Directors unanimously approved on Thursday the planned acquisition of SKNY Pharmaceuticals, Inc., following the completion of independent valuation reports on both companies. In March, MIRA Pharmaceuticals signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals. Under the terms, MIRA will acquire SKNY through a stock exchange, whereby SKNY shareholders will receive shares of MIRA common stock at a valuation determined by an independent third-party firm. Also Read: EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study A third-party analysis conducted by Moore Financial Consulting assigned SKNY Pharmaceuticals an enterprise value of approximately $30.5 million, based on a risk-adjusted net present value (rNPV) of its lead compound, SKNY-1. Mira was separately valued at $30 million, further validating the strength and synergy of the combined pipeline. As outlined in the binding letter of intent, the transaction includes a $5 million contribution from SKNY to Mira in cash or other assets, to be transferred at closing. The company is preparing a filing with the U.S. Securities and Exchange Commission to seek shareholder approval. As Mira advances this merger, the combined enterprise value of over $60 million, grounded in third-party analysis, represents a strong platform for expansion into high-value therapeutic markets. Mira CEO Erez Aminov said the acquisition “brings together two pipelines, two market opportunities, and one unified strategy: developing targeted, first-in-class therapies for urgent public health needs.” SKNY-1 is being developed as a next-generation oral therapeutic designed to modulate CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B)—an enzyme involved in dopamine metabolism and addiction regulation. On Tuesday, MIRA Pharmaceuticals released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist. The U.S. Food and Drug Administration (FDA) required the study before initiating human dosing in the United States. The preclinical study showed no evidence of brain toxicity, including the absence of Olney lesions—vacuolar brain changes historically associated with older NMDA-targeting drugs such as ketamine and MK-801. These results further confirm the favorable safety profile of Ketamir-2 and support its safe continued clinical development. Price Action: At the last check Thursday, MIRA stock was down 2.59% at $1.12 during the premarket session. Story Continues Read Next: Long-Term Decline In Cereal Market Poses Structural Challenges For Kellogg, Analyst Says Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million originally appeared on Benzinga.com © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...